Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for posttraumatic stress disorder (PTSD). For more information, please visit www.recoverystudy.com or www.clinicaltrials.gov (NCT03841773).

Financial Info
: Financials

Financials

v3.19.2
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 12,150 $ 25,034
Prepaid expenses and other 2,009 1,022
Total current assets 14,159 26,056
Property and equipment, net 36 43
Operating lease right-of-use assets 580  
Security deposit 13  
Restricted cash 100 100
Intangible asset 120 120
Total assets 15,008 26,319
Current liabilities:    
Accounts payable 1,044 1,404
Accrued expenses and other current liabilities 562 1,251
Operating lease liabilities, current 441  
Total current liabilities 2,047 2,655
Operating lease liabilities, noncurrent 139  
Total liabilities 2,186 2,655
Commitments (See Note 10)  
Stockholders' equity:    
Preferred stock, $0.001 par value; 5,000,000 shares authorized Series A Convertible Preferred stock, $0.001 par value; 11,984 shares designated; 0 and 9,856 shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively
Common stock, $0.001 par value; 150,000,000 shares authorized; 6,338,320 and 3,251,970 shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively, and 23,792 and 1,758 shares to be issued as of June 30, 2019 and December 31, 2018, respectively 6 3
Additional paid in capital 213,380 212,154
Accumulated deficit (200,525) (188,452)
Accumulated other comprehensive loss (39) (41)
Total stockholders' equity 12,822 23,664
Total liabilities and stockholders' equity $ 15,008 $ 26,319
v3.19.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
COSTS AND EXPENSES:        
Research and development $ 3,554 $ 4,067 $ 7,450 $ 9,237
General and administrative 2,352 2,076 4,753 3,894
Total costs and expenses 5,906 6,143 12,203 13,131
Operating loss (5,906) (6,143) (12,203) (13,131)
Interest income, net 66 56 130 109
Net loss $ (5,840) $ (6,087) $ (12,073) $ (13,022)
Net loss per common share, basic and diluted (in dollars per share) $ (0.95) $ (7.23) $ (2.19) $ (15.98)
Weighted average common shares outstanding, basic and diluted (in shares) 6,167,012 842,041 5,511,249 815,120
v3.19.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (12,073) $ (13,022)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 16 30
Stock-based compensation 736 808
Changes in operating assets and liabilities:    
Prepaid expenses (987) (444)
Accounts payable (358) 342
Operating lease liabilities 2
Accrued expenses and other liabilities (691) 30
Net cash used in operating activities (13,355) (12,256)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of furniture and fixtures (10) (4)
Net cash used by investing activities (10) (4)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from exercise of warrants 70
Proceeds, net of $1 and $95 expenses, from sale of common stock 420 3,462
Net cash provided by financing activities 490 3,462
Effect of currency rate change on cash (9) (19)
Net decrease in cash, cash equivalents and restricted cash (12,884) (8,817)
Cash, cash equivalents and restricted cash beginning of the period 25,134 25,585
Cash, cash equivalents and restricted cash end of period 12,250 16,768
Non-cash financing activities:    
Issuance of common stock under employee benefit plan $ 3